CABA
CABALETTA BIO INC
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. It is focused on the discovery and development of engineered T-cell therapies for B-cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s product candidates include DSG3-CAART, DSG3/1-CAART, MuSK-CAART, PLA2R-CAART, and FVIII-CAART. DSG3-CAART is evaluated for the treatment of mucosal pemphigus vulgaris (mPV), a subtype of pemphigus vulgaris (PV) that affects the epithelium of the mucous membranes. DSG3/1-CAART is designed for mucocutaneous pemphigus vulgaris (mcPV). MuSK-CAART is designed for the treatment of muscle-specific kinase (MuSK) and myasthenia gravis (MG). PLA2R-CAART is developed to treat phospholipase A2 receptor (PLA2R) associated membranous nephropathy. FVIII-CAART, which is being designed to treat a subset of patients with Hemophilia A.
Buy US stocks in Australia starting with CABA. Open an account and start investing today!
$360.47M
-
0.00%
0
$12.82
$12.00
$0.00
$12.82
$0.59
CABA FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CABA
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.